Loading...
  • immunity
  • Dr. Berzofsky pioneered characterization of B- and T-cell epitopes and their modification to make epitope-enhanced vaccines, discovered the importance of T cell avidity in viral/tumor clearance, pioneered use of defined molecular adjuvants to alter quality of immune responses, advanced mucosal HIV vaccines, discovered NKT cell regulation of tumor immunity, and blocked negative regulation by TGF-beta, IL-13, and regulatory cells to enhance tumor immunity and vaccine efficacy. (cancer.gov)
  • Adoptive transfer of HCMV-specific T cells has emerged as an effective method to reduce the risk for HCMV infection and/or reactivation by restoring immunity in transplant recipients. (frontiersin.org)
  • However, the CMV-specific CD8 + T cell response is comprised of a heterogenous mixture of subsets with distinct functions and localization, and it is not clear if current adoptive immunotherapy protocols can reconstitute the full spectrum of CD8 + T cell immunity. (frontiersin.org)
  • The aim of this review is to briefly summarize the role of these T cell subsets in CMV immunity and to describe how current adoptive immunotherapy practices might affect their reconstitution in patients. (frontiersin.org)
  • dendritic
  • Immunotherapies such as the dendritic cell (DC) vaccine, heat shock protein vaccines, and epidermal growth factor receptor (EGFRvIII) vaccines have shown encouraging results in clinical trials, and have demonstrated synergistic effects with conventional therapeutics resulting in ongoing phase III trials. (mdpi.com)
  • cancer
  • As chief, he oversees the Vaccine Branch's basic, translational, and clinical research in cancer and retroviral vaccines and immunotherapy. (cancer.gov)
  • Our research focuses on elucidating new fundamental principles governing T cell activation, regulation, and effector function, and employing these to develop more effective vaccine and immunotherapy strategies for HIV, cancer, and viruses causing cancer. (cancer.gov)
  • Immunotherapy such as cancer vaccines have shown encouraging results in phase I and II clinical trials, and have even demonstrated synergistic effects with standard therapy [ 17 , 18 , 19 , 20 , 21 ]. (mdpi.com)
  • Clinical trials involving T cell-based immunotherapy for the treatment of human cancer have shown limited degrees of success. (aacrjournals.org)
  • Although such tolerance mechanisms have emerged as formidable barriers to immunotherapy, as discussed below, our knowledge of tumor-associated antigens for melanoma and other tumor types has provided potential molecular targets for T cell-based immunotherapy, and has allowed for the design of strategies to break immune tolerance for patients with cancer. (aacrjournals.org)
  • The section was founded with the Society for Immunotherapy of Cancer (SITC) under the title "Tumor immunology and biological cancer therapy" and Edited by Pedro Romero. (biomedcentral.com)
  • Targeting CHOP may overcome tumor-induced tolerance and enhance cancer immunotherapy. (aacrjournals.org)
  • paradigm
  • As a result of only modest improvements in survival emerging from the traditional triad of surgical excision, radiotherapy, and chemotherapy, there have been intensified research efforts studying immunotherapy as a more effective treatment paradigm [ 6 , 15 , 16 ]. (mdpi.com)
  • patients
  • For over 25 years, investigators have been exploring the potential for adoptive T cell therapy to combat these infections in severely immunocompromised patients. (frontiersin.org)
  • proliferation
  • Supraphysiologic T-cell proliferation, a hallmark of this therapy, contributes to both efficacy and the most notable toxicity, cytokine release syndrome (CRS), posing a unique challenge for toxicity management. (bloodjournal.org)